Find a company
Endoscopy is a rate limiting step in the diagnosis of oesophageal cancer, and the pandemic has only exacerbated pre-existing waiting lists and delays. We urgently need alternative technologies to support recovery of NHS services and shorten patient waiting times.
The Cytosponge test is a non-endoscopic test for the earlier detection of oesophageal cancer that is transforming the care pathway for people living with chronic reflux and Barrett’s Oesophagus. Cytosponge can be used to triage those on endoscopy waiting lists and who present to their GPs with symptoms to identify those at most risk of cancer to prioritise for endoscopy. Project CYTOPRIME will pilot the Cytosponge test in the community to support recovery of endoscopy services across the North West Coast.
| Project | Project CYTOPRIME - Cytosponge in Primary and Community Care |
|---|---|
| Description |
Endoscopy is a rate limiting step in the diagnosis of oesophageal cancer, and the pandemic has only exacerbated pre-existing waiting lists and delays. We urgently need alternative technologies to support recovery of NHS services and shorten patient waiting times. The Cytosponge test is a non-endoscopic test for the earlier detection of oesophageal cancer that is transforming the care pathway for people living with chronic reflux and Barrett’s Oesophagus. Cytosponge can be used to triage those on endoscopy waiting lists and who present to their GPs with symptoms to identify those at most risk of cancer to prioritise for endoscopy. Project CYTOPRIME will pilot the Cytosponge test in the community to support recovery of endoscopy services across the North West Coast. |
| Funding | £ 416,483 |
| Competition | Competition 19 - NHS Reset and Recovery and New Ways of Working |
| Competition Date | August 2021 |
| Categories | Cancer |
| Health Innovation Network Partner | Health Innovation East Midlands , UCL Partners |
| Website | https://cyted.ai |
Endoscopy is a rate limiting step in the diagnosis of oesophageal cancer, and the pandemic has only exacerbated pre-existing waiting lists and delays. We urgently need alternative technologies to support recovery of NHS services and shorten patient waiting times.
The Cytosponge test is a non-endoscopic test for the earlier detection of oesophageal cancer that is transforming the care pathway for people living with chronic reflux and Barrett’s Oesophagus. Cytosponge can be used to triage those on endoscopy waiting lists and who present to their GPs with symptoms to identify those at most risk of cancer to prioritise for endoscopy. Project CYTOPRIME will pilot the Cytosponge test in the community to support recovery of endoscopy services across the North West Coast.
| Project | Project CYTOPRIME2: Earlier Oesophageal Cancer Detection in Primary Care |
|---|---|
| Description |
This non-endoscopic test for the earlier detection of oesophageal cancer is transforming the care pathway for people living with chronic reflux. Project CYTOPRIME2 will test patients at risk of cancer in primary and community care across the East of England, North West Coast and Wessex Cancer Alliance regions. |
| Funding | £ 3,664,173 |
| Competition | NHS Cancer Programme – Innovation Open Call – Competition 2 |
| Competition Date | February 2022 |
| Health Innovation Network Partner | Health Innovation East Midlands , UCL Partners |
| Website | https://cyted.ai |
Endoscopy is a rate limiting step in the diagnosis of oesophageal cancer, and the pandemic has only exacerbated pre-existing waiting lists and delays. We urgently need alternative technologies to support recovery of NHS services and shorten patient waiting times.
The Cytosponge test is a non-endoscopic test for the earlier detection of oesophageal cancer that is transforming the care pathway for people living with chronic reflux and Barrett’s Oesophagus. Cytosponge can be used to triage those on endoscopy waiting lists and who present to their GPs with symptoms to identify those at most risk of cancer to prioritise for endoscopy. Project CYTOPRIME will pilot the Cytosponge test in the community to support recovery of endoscopy services across the North West Coast.
| Project | The Community Pharmacy Assessment for Barrett’s Oesophagus and Reflux Symptoms (Project COMPASS) |
|---|---|
| Description |
Oesophageal adenocarcinoma (OAC) has one of the worst prognoses in the UK, with most people diagnosed too late for treatment to be effective. The EndoSign ® capsule sponge test offers a fast and simple way to detect and monitor Barrett’s oesophagus, a precursor to OAC. Through Project COMPASS, Cyted Health is offering capsule sponge testing in pharmacies across the East Midlands and North Central London. The project will identify at-risk individuals by tracking reflux medication purchases and reaching underserved communities in the two regions. |
| Funding | £ 1,849,778 |
| Competition | NHS Cancer Programme - Innovation Open Call 3 |
| Competition Date | April 2024 |
| Categories | Cancer |
| Health Innovation Network Partner | Health Innovation East Midlands , UCL Partners |
| Website | https://cyted.ai |